東陽光(600673.SH)終止收購生化製藥100%股權
格隆匯5月21日丨東陽光(600673.SH)公佈,2021年5月21日,公司召開了第十一屆董事會第三次會議和第十一屆監事會第三次會議,審議通過了《關於終止重大資產重組事項的議案》,同意公司終止該次重大資產重組事項。
此前公吿披露,為進一步整合優質醫藥製造類資產,擴充大環內酯類原料藥與中間體、鹽酸林可黴素原料藥與中間體、酶製劑等業務,實現產業鏈延伸,進一步增強公司未來的整體盈利能力,公司擬以發行股份方式購買宜昌東陽光藥業股份有限公司持有的宜昌東陽光生化製藥有限公司100%股權,同時,非公開發行股份募集配套資金。
基於交易對方內部資產下沉進程以及目前市場環境等原因,經審慎研究分析,公司及交易對方認為現階段繼續推進該次重組方案時間長、不確定性較大,為切實維護公司及全體股東利益,決定終止該次重組事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.